Peter S. Kim

Partially fueled by the human immunodeficiency virus (HIV) pandemic, tuberculosis is the second-leading cause of infectious diseases–associated mortality globally and the leading cause of death among those infected with HIV. In 2010, there were an estimated 8.8 million incident cases of tuberculosis and approximately 1.5 million deaths attributed to tuberculosis. Increased public heath efforts have been effective in decreasing the overall prevalence and mortality associated with this disease, but declines in incidence rates have been outpaced by global population growth, such that absolute incidence rates have not declined as fast as previously expected [1]. Commensurate with increased public recognition of the importance of tuberculosis to global health in the mid-1990s, biomedical research for tuberculosis has increased both in the United States and internationally. Although tools to conduct modern biomedical research involving tuberculosis have only been available for a little over a decade, this research has resulted in several successes, including promising new vaccines to protect against tuberculosis in the highest-risk populations, diagnostic candidates to improve the accuracy and speed of diagnosing all forms of tuberculosis, and new drug candidates with the potential for improved treatment and chemoprevention for drug-sensitive and drug-resistant tuberculosis.